Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Emily Stepanchick"'
Autor:
Ashley E. Culver-Cochran, Marie-Dominique Filippi, Joshua R. Bennett, Kathleen Hueneman, Emily Stepanchick, James Bartram, Mark Wunderlich, John P. Perentesis, Daniel T. Starczynowski, Timothy M. Chlon, Lyndsey Bolanos, Madeline Niederkorn, Emma Uible, Kwangmin Choi, Chiharu Ishikawa
Publikováno v:
Leukemia
Ubiquitin-specific peptidase 15 (USP15) is a deubiquitinating enzyme implicated in critical cellular and oncogenic processes. We report that USP15 mRNA and protein are overexpressed in human acute myeloid leukemia (AML) as compared to normal hematopo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2e7d2bb59628468f7859a7a88e84f6d
https://doi.org/10.1038/s41375-021-01394-z
https://doi.org/10.1038/s41375-021-01394-z
Publikováno v:
Blood Cancer Discovery. 4:A46-A46
Germline mutations in the RNA Helicase gene DDX41 are the most common cause of inherited susceptibility to adult MDS and AML. These mutations are always heterozygous and are typically frameshifts, causing loss of functional protein. We recently repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::370116e8c92156a62fa988ff8e532a5d
https://doi.org/10.1158/2643-3249.aml23-a46
https://doi.org/10.1158/2643-3249.aml23-a46
Autor:
Courtney E Hershberger, Kathleen Hueneman, Daniel T. Starczynowski, Torsten Haferlach, Yi Zheng, Emily Stepanchick, Ashley Kuenzi Davis, Carmelo Gurnari, Jaroslaw P. Maciejewski, Noah J. Daniels, Richard A. Padgett, Timothy M. Chlon, Kwangmin Choi
Publikováno v:
Cell Stem Cell
DDX41 mutations are the most common germline alterations in adult myelodysplastic syndromes (MDSs). The majority of affected individuals harbor germline monoallelic frameshift DDX41 mutations and subsequently acquire somatic mutations in their other
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5f96fe73f1557f06df3afc7c5533331
https://pubmed.ncbi.nlm.nih.gov/34473945
https://pubmed.ncbi.nlm.nih.gov/34473945
Autor:
Kathleen Hueneman, Daniel T. Starczynowski, Emily Stepanchick, Analise Sulentic, Timothy M. Chlon
Publikováno v:
Blood. 138:148-148
Germline mutations in the RNA Helicase gene DDX41 cause inherited susceptibility to Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). These mutations are always heterozygous and are typically frameshifts, causing loss of protein expres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48f554c89a0a56c869f4d952d16ef880
https://doi.org/10.1182/blood-2021-153544
https://doi.org/10.1182/blood-2021-153544
Autor:
Regina Aquino, Yang Liu, Jennifer Yang, Sriram Balasubramanian, Matthias Versele, Michael Schaffer, Shalini Chaturvedi, Rongzhen Lu, Cuc Davis, Emily Stepanchick
Publikováno v:
Leukemia & Lymphoma. 59:931-940
Matrix high-throughput screening (HTS) methods are increasingly employed to rapidly define potential therapeutic drug combinations. We used combination HTS to identify compounds showing synergistic anti-proliferative activity with ibrutinib, an irrev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8ca5fe18470864ab22b8bcf3d0cc760
https://doi.org/10.1080/10428194.2017.1349899
https://doi.org/10.1080/10428194.2017.1349899
Publikováno v:
Blood. 136:40-40
Germline mutations in the DEAD-box RNA helicase gene DDX41 cause inherited susceptibility to Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). These patients have normal hematopoietic indices into adulthood and present with MDS at a me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccd2abd4fe1d5e0d7dd6a5182fda0574
https://doi.org/10.1182/blood-2020-143222
https://doi.org/10.1182/blood-2020-143222
Autor:
Ashley Kuenzi Davis, Timothy M. Chlon, Emily Stepanchick, Kathleen Hueneman, Yi Zheng, Daniel T. Starczynowski, Kwangmin Choi
Publikováno v:
Blood. 134:773-773
Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) disorders in which myeloid cell differentiation is impaired, causing blood lineage cytopenias and potentially leading to acute myeloid leukemia (AML) through malignant transformation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8283edd0ad0b92148d637f6d0ade2827
https://doi.org/10.1182/blood-2019-127471
https://doi.org/10.1182/blood-2019-127471
Autor:
Sriram Balasubramanian, Cuc Davis, Emily Stepanchick, Matthias Versele, Regina Aquino, Michael Schaffer, Shalini Chaturvedi
Publikováno v:
Cancer Research. 76:365-365
The primary objective of this study was to discover synergies leading to mechanistic insights and novel combinations for ibrutinib, a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib has been approved for relapsed/refractory (R/R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bd5c3c21797130f98e4e0859d8e692b
https://doi.org/10.1158/1538-7445.am2016-365
https://doi.org/10.1158/1538-7445.am2016-365
Autor:
Sriram Balasubramanian, Nele Fourneau, Yasuhiro Oki, Regina Aquino, Shalini Chaturvedi, Cuc Davis, Emily Stepanchick, Michael Schaffer, Anas Younes
Publikováno v:
Blood. 124:2965-2965
Introduction The primary objective of the DBL1002 study was to determine the recommended phase 2 dose and assess dose limiting toxicities of ibrutinib in combination with R-CHOP in subjects with CD20-positive B-cell NHL (diffuse large B-cell lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58fb11a51f849be408271d6e3cc8cc8a
https://doi.org/10.1182/blood.v124.21.2965.2965
https://doi.org/10.1182/blood.v124.21.2965.2965
Autor:
Georg Lenz, Zhilong Yuan, Michael Wang, Simon Rule, Sriram Balasubramanian, Irit Avivi, Cuc Davis, Emily Stepanchick, Britte Kranenburg, William Deraedt, Sen Hong Zhuang, Regina Aquino, Aleksandra Rizo, Martin Dreyling, Michael Schaffer
Publikováno v:
Blood. 124:78-78
Introduction: Ibrutinib, a first-in-class, once-daily, oral covalent inhibitor of Bruton’s tyrosine kinase is highly effective in relapsed or refractory mantle cell lymphoma (MCL) patients with an ORR of 68% (Wang M, et al. N Engl J Med. 2013;369:5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f693fb6e2ce42ce07677dab44cbd2a8
https://doi.org/10.1182/blood.v124.21.78.78
https://doi.org/10.1182/blood.v124.21.78.78